Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
1999 1
2001 2
2002 2
2003 1
2004 2
2009 1
2010 1
2011 2
2013 2
2017 1
2019 1
2024 1
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Meloxicam.
Fleischmann R, Iqbal I, Slobodin G. Fleischmann R, et al. Expert Opin Pharmacother. 2002 Oct;3(10):1501-12. doi: 10.1517/14656566.3.10.1501. Expert Opin Pharmacother. 2002. PMID: 12387696 Review.
Meloxicam (Mobic trade mark, Boehringer Ingelheim) is a relatively new oral non-steroidal anti-inflammatory drug (NSAID) approved for the treatment of osteoarthritis in the US. It has also been evaluated for the treatment of rheumatoid arthritis, ankylosing spondylitis and …
Meloxicam (Mobic trade mark, Boehringer Ingelheim) is a relatively new oral non-steroidal anti-inflammatory drug (NSAID) approved for …
[Meloxicam].
Sternon J, Appelboom T. Sternon J, et al. Rev Med Brux. 1998 Feb;19(1):29-32. Rev Med Brux. 1998. PMID: 9553452 Review. French.
NSAID's are currently medications widely prescribed. Meloxicam is a new oxicam which has a low COX-2/COX-1 ratio, i.e. it has an inhibitory effect focused on the inflammatory proteins (COX-2) with relative saving of the homeostatic proteins (COX-1). This molecule has been …
NSAID's are currently medications widely prescribed. Meloxicam is a new oxicam which has a low COX-2/COX-1 ratio, i.e. it has an inhi …
Meloxicam--a safer NSAID?
[No authors listed] [No authors listed] Drug Ther Bull. 1998 Aug;36(8):62-4. Drug Ther Bull. 1998. PMID: 9876404 Review. No abstract available.
Individualizing NSAID therapy in axial spondyloarthritis: N-of-1 trials with Bayesian analysis.
Hwang MC, Kim S, Assassi S, Chavez R, Samuel J, Green C, Tyson J, Reveille J. Hwang MC, et al. Rheumatology (Oxford). 2025 Dec 1;64(12):6114-6121. doi: 10.1093/rheumatology/keaf393. Rheumatology (Oxford). 2025. PMID: 40676732 Free PMC article. Clinical Trial.
OBJECTIVE: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease predominantly affecting the spine and sacroiliac joints. ...We evaluated the efficacy and patient preference of three NSAIDs (celecoxib, meloxicam and naproxen) through Bayesian N-of-1 clin …
OBJECTIVE: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease predominantly affecting the spine and sacroiliac joints. …
Immunoglobulin A vasculitis and pustular psoriasis precipitated by Tawon Liar: a case report.
Zha M, Ding DD. Zha M, et al. J Med Case Rep. 2025 May 30;19(1):259. doi: 10.1186/s13256-025-05167-5. J Med Case Rep. 2025. PMID: 40448236 Free PMC article.
The supplement, obtained from a coworker, contained undisclosed ingredients including meloxicam, ketorolac, and dexamethasone. Laboratory tests ruled out renal involvement, and biopsies were not performed due to financial constraints. ...
The supplement, obtained from a coworker, contained undisclosed ingredients including meloxicam, ketorolac, and dexamethasone. Labora …
ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis.
Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D. Dougados M, et al. Ann Rheum Dis. 2011 Feb;70(2):249-51. doi: 10.1136/ard.2010.133488. Epub 2010 Sep 9. Ann Rheum Dis. 2011. PMID: 20829199
For the NSAID equivalent scoring system, the recommendations are (1) to refer to a scale in which 0 = no intake, 100 = 150 mg diclofenac, 1000 mg naproxen, 200 mg aceclofenac, 400 mg celecoxib, 600 mg etodolac, 90 mg etoricoxib, 200 mg flurbiprofen, 2400 mg ibuprofen, 150 mg indo …
For the NSAID equivalent scoring system, the recommendations are (1) to refer to a scale in which 0 = no intake, 100 = 150 mg diclofenac, 10 …
Aquaporin-1 expression as an indicator in evaluating the efficacy of meloxicam in the treatment of ankylosing spondylitis: A comparative study.
Pan JE, Xiong FL, Chen G, Zhang ZW, Xu YJ. Pan JE, et al. Biomed Pharmacother. 2017 Nov;95:1549-1555. doi: 10.1016/j.biopha.2017.08.093. Epub 2017 Sep 22. Biomed Pharmacother. 2017. PMID: 28950654 Clinical Trial.
Correlation of expressions of AQP1, efficacy of meloxicam and expression of pro-inflammatory cytokines were determined via Pearson correlation analysis. ...CONCLUSION: Our findings indicated that AQP1 was both highly expressed and positively correlated with the efficacy of …
Correlation of expressions of AQP1, efficacy of meloxicam and expression of pro-inflammatory cytokines were determined via Pearson co …
Assessment of liver and kidney function in patients with ankylosing spondylitis on long-term non-steroidal anti-inflammatory drug therapy.
Sülükcü S, Uslu S. Sülükcü S, et al. Reumatismo. 2024 Sep 24;76(4). doi: 10.4081/reumatismo.2024.1732. Reumatismo. 2024. PMID: 39315555 Free article.
Of them, 44.6% used indomethacin, 26.8% naproxen, 17.9% diclofenac, 5.4% acemetacin, 3.6% meloxicam, and 1.8% celecoxib. The mean baseline serum creatinine was 0.71 mg/dL. The mean baseline serum AST and ALT were 19.6 u/L and 22.9 u/L, respectively. ...
Of them, 44.6% used indomethacin, 26.8% naproxen, 17.9% diclofenac, 5.4% acemetacin, 3.6% meloxicam, and 1.8% celecoxib. The mean bas …
Current Trends in NSAID Prescribing for Osteoarthritis and Axial Spondyloarthritis: Insights From Moroccan Rheumatologists Practices.
El Binoune I, Zineb B, Rostom S, Amine B, Bahiri R. El Binoune I, et al. Health Sci Rep. 2026 May 20;9(5):e71764. doi: 10.1002/hsr2.71764. eCollection 2026 May. Health Sci Rep. 2026. PMID: 42254302 Free PMC article.
BACKGROUND AND AIMS: Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the cornerstone of symptomatic management in osteoarthritis (OA) and axial spondyloarthritis (axial SpA), but safety concerns have reshaped prescribing behaviors. This study aimed to describe current …
BACKGROUND AND AIMS: Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the cornerstone of symptomatic management in osteoarthritis (OA) a …
[Methotrexate in conjunction with meloxicam for treating ankylosing spondylitis: a clinical observation of the efficacy and safety].
Xie RL, Li XH, Kang XT. Xie RL, et al. Di Yi Jun Yi Da Xue Xue Bao. 2003 May;23(5):460-2. Di Yi Jun Yi Da Xue Xue Bao. 2003. PMID: 12754130 Clinical Trial. Chinese.
CONCLUSION: The combination of methotrexate with meloxicam may achieve satisfactory results in AS treatment, which is not positively related to methotrexate dosage. In short-term usage, meloxicam does not increase the toxicity of methotrexate....
CONCLUSION: The combination of methotrexate with meloxicam may achieve satisfactory results in AS treatment, which is not positively …
22 results